| Literature DB >> 30721261 |
Mei-Wen Chen1,2, Chien-Pin Chan3, Yih-Jeng Lin2, Hsu-Heng Yen4,5.
Abstract
BACKGROUND: A hybrid topographic and numeric lymph node (LN) staging system for gastric cancer, which was recently proposed by Japanese experts as a simple method with a prognostic predictive power comparable to the N staging of the American Joint Committee on Cancer (AJCC) Tumor-node-metastasis classification, has not yet been validated in other Asian countries. This study aimed to examine the prognostic predictability of the hybrid staging system with the current AJCC staging system in gastric cancer.Entities:
Mesh:
Year: 2019 PMID: 30721261 PMCID: PMC6363228 DOI: 10.1371/journal.pone.0211836
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of lymph classification between AJCC 7th system and Anatomical location-based nodal staging system.
| N Stage | AJCC 7th | Anatomical location-based nodal staging system |
|---|---|---|
| N0 | 0 | 0 |
| N1 | 1–2 lymph nodes | Involvement one of LC/GC/EP Groups |
| N2 | 3–6 lymph nodes | Involvement two of LC/GC/EP Groups |
| N3 | ≥7 lymph nodes | Involvement all of LC/GC/EP Groups |
Abbrevations for Table 1. LC Group: lesser curvature lymph node group. GC Group: greater curvature lymph node group. EP: Group: extra-perigastric lymph node group
Characteristics and overall survival rate of patients with gastric cancer.
| Variables | Patients (%) | 5 y OS (%) | mean OS | |
|---|---|---|---|---|
| 66.24 ± 12.29 | .001 | |||
| .588 | ||||
| Man | 248 (62.00) | 47.576 | 5.801 (4.998–6.604) | |
| Female | 152 (38.00) | 50.102 | 5.228 (4.674–5.782) | |
| .001 | ||||
| C161, fundus of stomach | 7 (1.75) | 0.000 | 2.404 (1.121–3.686) | |
| C162, body of stomach | 93 (23.25) | 51.745 | 6.073 (5.046–7.100) | |
| C163, gastric antrum | 221 (55.25) | 52.191 | 5.759 (5.127–6.391) | |
| C164, pylorus | 32 (8.00) | 46.276 | 4.172 (3.165–5.179) | |
| C165, lesser curvature of stomach, NOS | 17 (4.25) | 71.500 | 6.535 (4.744–8.326) | |
| C166, greater curvature of stomach, NOS | 2 (0.50) | 0.000 | 0.697 (0.000–1.715) | |
| C168, overlapping lesion of stomach | 28 (7.00) | 14.286 | 5.510 (5.028–5.992) | |
| .616 | ||||
| G1, well; G2, moderately differentiated | 112 (28.00) | 46.829 | 5.110 (4.293–5.927) | |
| G3, poorly differentiated/undifferentiated | 288 (72.00) | 49.029 | 5.573 (5.006–6.139) | |
| .001 | ||||
| 1A, lamina propria or muscularis mucosae | 30 (7.50) | 95.000 | 9.718 (8.705–10.731) | |
| 1B, submucosa | 50 (12.50) | 80.862 | 8.563 | |
| 2, muscularis propria | 57 (14.25) | 64.798 | 6.729 | |
| 3, subserosa | 137 (34.25) | 47.064 | 5.060 | |
| 4A, serosa (visceral peritoneum) | 105 (26.25) | 20.287 | 3.070 | |
| 4B, adjacent structures | 21 (5.25) | 14.435 | 2.261 | |
| .001 | ||||
| 0 | 139 (34.75) | 76.514 | 8.136 (7.411–8.861) | |
| 1, 1–2 | 58 (14.50) | 47.923 | 4.969 (4.048–5.890) | |
| 2, 3–6 | 68 (17.00) | 49.265 | 5.178 (4.273–6.083) | |
| 3, ≥7 | 135 (33.75) | 18.827 | 2.847 (2.270–3.425) | |
| .001 | ||||
| 1A | 68 (17.00) | 90.368 | 9.452 (8.680–10.224) | |
| 1B | 30 (7.50) | 78.923 | 8.405 (7.059–9.750) | |
| 2A | 52 (13.00) | 57.992 | 5.651 (4.592–6.710) | |
| 2B | 43 (10.75) | 65.514 | 6.118 (5.028–7.208) | |
| 3A | 55 (13.75) | 41.586 | 4.906 (3.922–5.889) | |
| 3B | 50 (12.50) | 33.726 | 4.170 (3.196–5.145) | |
| 3C | 57 (14.25) | 12.558 | 2.349 (1.471–3.223) | |
| 4 | 45 (11.25) | 12.529 | 1.935 (1.202–2.669) | |
| .001 | ||||
| 1A | 68 (17.00) | 90.368 | 9.452 (8.680–10.224) | |
| 1B | 30 (7.50) | 78.923 | 8.405 (7.059–9.750) | |
| 2A | 56 (14.00) | 56.103 | 5.478 (4.463–6.494) | |
| 2B | 53 (13.25) | 62.225 | 6.387 (5.363–7.412) | |
| 3A | 51 (12.75) | 39.563 | 4.334 (3.383–5.284) | |
| 3B | 48 (12.00) | 26.861 | 3.719 (2.685–4.753) | |
| 3C | 49 (12.25) | 13.138 | 2.494 (1.569–3.419) | |
| 4 | 45 (11.25) | 12.529 | 1.935 (1.202–2.669) | |
| No. of resected lymph nodes | .834 | |||
| ≤27 | 144 (36.00) | 50.443 | 5.667 (4.840–6.495) | |
| >27 | 256 (64.00) | 47.500 | 5.408 (4.822–5.995) | |
| Lymph node position (New N staging) | .001 | |||
| | ||||
| | ||||
| LC alone | 35 | 57.345 | 6.038 (4.843–7.234) | |
| GC alone | 31 | 47.285 | 4.671 (3.408–5.934) | |
| EP alone | 12 | 53.571 | 4.746 (2.861–6.632) | |
| | ||||
| LC + GC | 31 | 46.316 | 4.289 (2.914–5.665) | |
| LC + EP | 20 | 23.325 | 3.213 (1.855–4.572) | |
| GC + EP | 26 | 20.380 | 3.348 (2.228–4.469) | |
| | ||||
| LC + GC + EP | 106 | 20.647 | 3.056 (2.364–3.749) | |
| | 97 | 50.250 | 5.187 (4.373–6.000) | |
| | 163 | 23.622 | 3.316 (2.762–3.870) |
Fig 1The survival curves according to the N status based on the 7th AJCC staging system (left) and the new hybrid anatomy-based system (right).
Fig 2The survival curves according to the stage based on the 7th AJCC staging system (left) and the new hybrid anatomy-based system (right).
The distribution of patients according to the 7th AJCC staging system and the new hybrid staging system.
| 68 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 0 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| 0 | 0 | 49 | 7 | 0 | 0 | 0 | 0 | |||
| 0 | 0 | 3 | 32 | 18 | 0 | 0 | 0 | |||
| 0 | 0 | 0 | 4 | 29 | 16 | 2 | 0 | |||
| 0 | 0 | 0 | 0 | 8 | 33 | 7 | 0 | |||
| 0 | 0 | 0 | 0 | 0 | 1 | 48 | 0 | |||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 | |||
| Kappa = 0.810 | ||||||||||
| 139 | 0 | 0 | 0 | |||||||
| 0 | 48 | 26 | 4 | |||||||
| 0 | 10 | 35 | 32 | |||||||
| 0 | 0 | 7 | 99 | |||||||
| Kappa = 0.729 | ||||||||||
Computed by inter-rater agreement analysis and kappa value, where a kappa value of 0.20 indicates poor agreement and a kappa value of 0.80 indicates very good agreement. Concordance between the 7th AJCC stage and the new hybrid stage, kappa = 0.810. Concordance between the current N stage and new N stage, kappa value = 0.729.
The prognostic performance of each staging system by Harrell’s C-index.
| 0.713 | 0.662–0.764 | .001 | |
| 0.705 | 0.654–0.757 | .001 | |
| 0.771 | 0.725–0.816 | .001 | |
| 0.764 | 0.718–0.810 | .001 | |
| 0.626 | 0.522–0.730 | .022 | |
| 0.639 | 0.535–0.742 | .011 | |
| 0.699 | 0.602–0.796 | .001 | |
| 0.716 | 0.621–0.812 | .001 | |
| 0.746 | 0.688–0.803 | .001 | |
| 0.734 | 0.676–0.791 | .001 | |
| 0.800 | 0.750–0.850 | .001 | |
| 0.791 | 0.740–0.842 | .001 |
CI, confidence interval
Comparison of the prognostic performance between the 7th AJCC staging system and the new hybrid staging system for nodal and TNM stages.
| Likelihood Ratio | 62.136 | 58.309 | 99.432 | 95.846 |
| Linear Trend | 58.863 | 53.272 | 83.977 | 81.588 |
| Likelihood Ratio | 6.030 | 9.904 | 15.836 | 18.031 |
| Linear Trend | 5.491 | 6.435 | 9.790 | 10.779 |
| Likelihood Ratio | 61.555 | 56.909 | 91.467 | 88.445 |
| Linear Trend | 57.743 | 49.664 | 77.985 | 73.676 |
*Likelihood Ratio chi-square test: higher values indicate better homogeneity (a small difference in overall survival among patients classified into the same group by the new system)
** Linear Trend chi-square test: higher values indicate better discriminatory power (patients classified into different groups have greater differences in overall survival) and monotonicity.
Prognostic performance between the current and new nodal and TNM stages by bootstrap analysis.
| Bootstrap analysis for N parameter | ||||||||
| 106.5 | 18.432 | 102.9 | 18.199 | −3.541 | 18.316 | −5.148 to −1.935 | <0.001 | |
| 84.322 | 15.023 | 81.981 | 14.915 | −2.340 | 14.969 | −3.654 to −1.028 | <0.001 | |
| Bootstrap analysis for N parameter | ||||||||
| 9.087 | 5.452 | 12.790 | 6.241 | 3.703 | 5.860 | 3.189 to 4.217 | 0.001 | |
| 6.297 | 4.568 | 7.206 | 4.848 | 0.903 | 4.710 | 0.496 to 1.322 | 0.001 | |
| Bootstrap analysis for N parameter | ||||||||
| 64.484 | 14.657 | 59.866 | 14.263 | −4.618 | 14.461 | −5.886 to −3.450 | 0.001 | |
| 58.424 | 12.950 | 50.378 | 12.310 | −8.046 | 12.634 | −9.154 to −6.938 | 0.001 | |
| Bootstrap analysis for TNM stage | ||||||||
| 64.922 | 15.105 | 61.204 | 14.723 | −3.718 | 14.915 | −5.026 to −2.410 | <0.001 | |
| 59.451 | 13.942 | 53.981 | 13.504 | −5.470 | 13.725 | −6.673 to −4.266 | <0.001 | |
| Bootstrap analysis for TNM stage (G1/G2) | ||||||||
| 23.505 | 8.831 | 25.590 | 9.092 | 2.086 | 8.962 | 1.299 to 2.872 | 0.001 | |
| 10.4739 | 5.785 | 11.400 | 5.882 | 0.924 | 5.834 | 0.4121 to 1.435 | 0.001 | |
| Bootstrap analysis for TNM stage (G3) | ||||||||
| 58.424 | 12.950 | 50.378 | 12.310 | −8.046 | 12.634 | −9.154~−6.938 | 0.001 | |
| 98.174 | 16.674 | 95.242 | 16.502 | −2.932 | 16.588 | −4.386~−1.477 | 0.001 | |
*1000 samples